Pfizer and Moderns pledges US Govt for 240 million doses of vaccine by March end

▴ Pfizer and Moderns pledges US Govt for 240 million doses of vaccine by March end
J&J also applied for emergency application

The United States can expect to see a total of 240 million doses of Covid-19 vaccine by the end of March, drug companies told a House subcommittee Tuesday.

Pfizer and Moderna -- the two companies with Covid-19 vaccines authorized for emergency use in the United States -- have pledged to make a combined total of 220 million doses available for shipment by the end of March. Meanwhile, Johnson & Johnson, which could secure emergency use authorization for its Covid-19 vaccine from the US Food and Drug Administration later this week, has pledged to make 20 million doses available in the same time frame.

"If the emergency use authorization is received this week, we hope to contribute to ending this pandemic as soon as possible," Dr Richard Nettles, J&J's vice president of medical affairs, told lawmakers.


Nettles said the company is prepared to immediately ship nearly 4 million doses upon authorization of the vaccine.
Executives from each of the vaccine makers, along with executives from AstraZeneca and Novavax, testified before the House Committee on Energy and Commerce Subcommittee on Oversight and Investigations on Tuesday.

A fourth Covid-19 vaccine could become available in the US in April, when AstraZeneca could secure FDA authorization of its vaccine. Dr Ruud Dobber, the executive vice president and president of AstraZeneca's biopharmaceuticals business unit, said the company will immediately release 30 million doses upon authorization of the vaccine and up to 50 million doses by the end of April.

Pfizer had expected to deliver 30 to 40 million doses to the US by the end of 2020 but only hit the 40 million mark last week. Moderna had been projected to deliver 20 million doses to the US by the end of 2020 but fell short by a week. When asked on Tuesday why they didn't deliver on time, executives for the companies said access to raw materials and manufacturing a product that had never been made before both contributed to the problem.
"We did initially experience some problems with the initial ramp up of our vaccine," John Young, Pfizer's chief business officer, said. "We particularly saw some rate-limiting steps for the raw materials," Young added.

Full Story

https://edition.cnn.com/2021/02/23/health/vaccines-doses-end-of-march/index.html 

Tags : #Pfizer #Moderna #BioNTech #CoronaVaccine #DrRudd #AstraZeneca #Novavax #JohnYoung

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024